M e d i a s e t G r o u p

Size: px
Start display at page:

Download "M e d i a s e t G r o u p"

Transcription

1 M e d i a s e t G r o u p 11 th May First Quarter Results

2 M e d i a s e t G r o u p BROADCASTING

3 MEDIASET Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0% 44.4% 2.2% 3.7% Stable Growth OTHER TERRESTRIAL 5.8% -0.6 Source: Auditel, Individuals BROADCASTING 3

4 MEDIASET Q Still Leader in Prime Time Individuals Commercial Target (15-64yrs) 45.0% 44.5% 46.6% 42.3% Source: Auditel BROADCASTING 4

5 MEDIASET Q Channel Ranking PRIME TIME Individuals yrs yrs RAI CANALE CANALE CANALE RAI RAI ITALIA ITALIA ITALIA RAI RAI RAI RAI RAI RAI RETE RETE RETE Source: Auditel BROADCASTING 5

6 MEDIASET Q CANALE 5: Audience Share PEAK TIME (21:00 23:00) Share Points Vs 1Q 2003 Share Points Vs 1Q 2003 INDIVIDUALS 24.6% +1,4 24.2% = yrs 25.7% % -0.5 Source: Auditel BROADCASTING 6

7 MEDIASET Q Ad Break Audience Performance PEAK TIME (21:00 23:00) Individuals Commercial Target (15-64yrs) 13.6% 31.7% Source: Auditel BROADCASTING 7

8 MEDIASET Q ITALIA 1: 3rd Channel in Prime Time Individuals 11.2% 9.5% Commercial Target (15-34yrs) 16.1% 8.8% Source: Auditel BROADCASTING 8

9 MEDIASET Q RETE4: Strong Growth PRIME TIME Share Points Vs 1Q 2003 INDIVIDUALS 9.0% +1.1 MALE TARGET 9.5% +1.7 Source: Auditel BROADCASTING 9

10 MEDIASET Q Ad Break Audience Performance 24 HOURS % Vs Estimated Impacts JANUARY FEBRUARY MARCH INDIVIDUALS HOUSEWIVES* +1.1 = yrs +3.0 = +4.9 Source: Auditel * Women over 20 yrs BROADCASTING 10

11 M e d i a s e t G r o u p ADVERTISING 2004 First Quarter Results

12 MEDIASET Q Advertising Revenues ml ADV Revenues +8.1% Vs 1Q Q Q Q ADVERTISING 12

13 MEDIASET Q 4-YEAR Advertising Trend Q Q Q Q Q Source: Infoadex Nielsen Estimates ADVERTISING 13

14 ITALIAN MARKET Q Advertising Trend by Sector 2004 vs 2003 FINANCE/INSURANCE TELECOM AUTOMOTIVE MEDIA & PUBLISHING RETAIL +33.6% +21.3% +12.8% +24.5% +46.2% ADVERTISING 14

15 MEDIASET Q Advertising by Sector 1Q2004 (ml ) 2004 vs vs 2002 FOOD % +2.7% NON FOOD % -7.5% AUTOMOTIVE % +2.0% FINANCE/INSURANCE % -28.7% TELECOM % +8.8% MEDIA & PUBLISHING % +22.4% ADVERTISING 15

16 MEDIASET Q New Clients Acquisition Policy Active Clients New Clients in 1Q New Clients Revenues 12.8 ml ADVERTISING 16

17 M e d i a s e t G r o u p BROADCASTING 2004 First Quarter Results

18 TELE Q TV Audience Share PRIME TIME Individuals Commercial Target 24,1 23,9 26,8 28,3 22,5 22,8 19,0 19,2 18,3 17,8 20,1 18,8 17,0 20,0 18,8 16, Source: Sofres, Prime Time, Individuals (4+ years), Commercial Target (13-54 years) BROADCASTING 18

19 TELE Q TV Audience Share 24 Hours Individuals Commercial Target 23,7 22,9 24,7 25,2 21,4 19,7 18,8 22,1 20,1 17,7 21,0 19,5 16,6 21,4 18,9 15, Source: Sofres, 24 hours, Individuals (4+ years), Commercial Target (13-54 years) BROADCASTING 19

20 M e d i a s e t G r o u p ADVERTISING 2004 First Quarter Results

21 TELECINCO Q Advertising Revenues +21.2% +28.2% ADV Revenues +21.2% Vs 1Q 2003 ( ml) Source: Publiespana ADVERTISING 21

22 M e d i a s e t G r o u p 2004 First Quarter Results

23 MEDIASET GROUP Consolidated Results ( ml.) 1Q Q 2003 Net Consolidated Revenues Operating Costs EBITDA Amortisation & Depreciation EBIT pre Goodwill Amortisation Tele5 Goodwill Amortisation EBIT Pre-Tax Profit (355.9) (209.8) (10.8) (309.1) (248.6) (10.8)

24 ITALIAN BUSINESS 24

25 MEDIASET ITALIAN BUSINESS Financial Results ( ml.) 1Q Q 2003 Net Consolidated Revenues Operating Costs EBITDA Amortisation & Depreciation EBIT Pre-Tax Profit (281.1) (168.4) (243.7) (199.6)

26 MEDIASET ITALIAN BUSINESS Operations Breakdown ( ml.) Total Net Revenues EBIT EBIT margin TV Operations % Non TV Operations % DTT Operations 3.8 (8.8) n.a % 26

27 MEDIASET ITALIAN BUSINESS TV Operations ( ml.) 1Q Q 2003 D % Total Net TV Revenues ,3% TV Advertising Revenues Other TV Revenues Sale of Rights Commissions (111.9) (102.2) Total TV Costs (418.8) (423.9) -1.2% Personnel (76.5) (74.8) TV Operating Costs (180.5) (152.8) TV Amortisations (144.3) (176.2) Other Amortisations & Depreciations (17.5) (20.0) EBIT from TV Operations ,0% margin 35.9% 31.1% 27

28 MEDIASET ITALIAN BUSINESS Non TV Operations ( ml.) 1Q Q 2003 Total Non TV Revenues Thematic Channels Teletext Internet Other Non-TV Revenues Total Non TV Costs Personnel Multimedia Operating Costs Non-TV Operating Costs Amortisations & Depreciations EBIT from Non TV Operations margin (18.0) (2.6) (6.3) (6.1) (3.0) % (19.0) (2.7) (6.2) (6.8) (3.3) % 28

29 MEDIASET ITALIAN BUSINESS DTT Operations ( ml.) 1Q Q 2003 Total DTT Revenues Total DTT Costs Personnel DTT Operating Costs Amortisations & Depreciations (12.7) (1.8) (7.3) (3.6) (0.4) (0.1) (0.3) (0.0) EBIT from DTT Operations (8.8) (0.4) 29

30 MEDIASET ITALIAN BUSINESS Non Operating Items ( ml.) 1Q Q 2003 ALBACOM (19.5% stake) Others Total Associates Net Financial Income/(Charges) Total Extraordinary Items (2.4) (0.1) (2.5) 1.4 (0.3) (10.3) - (10.3) (7.5) (0.1) 30

31 MEDIASET ITALIAN BUSINESS Cash Flow Statement ( ml.) 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Equity (Investments)/Disinvest. Dividends Cashed-in Dividends from Tele5 Total Net Cash Flow Net Financial Position 31/3 (451.4) (136.2) (95.1) (170.8) (133.8) - (53.4) (276.0) - - (74.5) (245.3) 31

32 MEDIASET ITALIAN BUSINESS Investments ml ml Q Q TV Rights Technical & Immaterial DTT investments ( ml.) 32

33 TELECINCO 33

34 TELECINCO Financial Results ( ml.) ITALIAN GAAP 1Q Q 2003 Total Net Revenues Total Costs Personnel Operating Costs Amortisation & Depreciation EBIT Pre-tax Profit (116.4) (16.8) (58.1) (41.5) (114.4) (16.1) (49.3) (49.0)

35 TELECINCO Cash Flow Statement ( ml.) ITALIAN GAAP 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Equity (Investments)/Disinvest. Dividends Total Net Cash Flow Net Financial Position 31/ (58.4) (52.6)

36 MEDIASET GROUP Back up Slides 36

37 MEDIASET GROUP Consolidated Results ( ml.) 1Q 2004 Consolidated 1Q 2004 Mediaset 1Q 2004 Telecinco Consolidation Effects Net Consolidated Revenues (0.1) Operating Costs (355.9) (281.1) (74.9) 0.1 EBITDA Amortisation & Depreciation (209.8) (168.4) (41.5) - EBIT pre Goodwill Amortisation Tele5 Goodwill Amortisation (10.8) - - (10.8) EBIT (10.8) Pre-Tax Profit (10.8) 37

38 MEDIASET GROUP Consolidated Cash Flow ( ml.) 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Change in Consolidation Area Equity (investments)/disinvest. Dividends Total Net Cash Flow Net Financial Position 31/3 (*): including 142.3m. Tele5 1/1/2003 Net Financial Position (199.3) (194.6) (170.8) (186.4) - (27.4) (133.7) * (59.5) 38

39 MEDIASET ITALIAN BUSINESS Back up Slides 39

40 MEDIASET ITALIAN BUSINESS Revenues Breakdown ( ml.) 1Q Q 2003 Total Net TV Revenues TV Advertising Revenues Other TV Revenues Sales of Rights Commissions Total Net Multimedia Revenues Non TV Revenues DTT Revenues Total Net Revenues (111.9) (102.2)

41 MEDIASET ITALIAN BUSINESS Operating Costs Breakdown ( ml.) 1Q Q 2003 Personnel Costs TV Operating Costs Commercial Costs In-house Production Transmission Costs Overheads Multimedia Operating Costs Non TV Operating Costs DTT Operating Costs Total Operating Costs (80.8) (180.5) (20.5) (138.0) (7.0) (15.0) (6.3) (6.1) (7.3) (281.1) (77.6) (152.8) (19.8) (111.0) (7.9) (14.1) (6.2) (6.8) (0.3) (243.7) 41

42 MEDIASET ITALIAN BUSINESS Amortisation & Depreciation -15.6% Depreciation And Other Amortisation ( ml.) ,0 +2.6% TV Rights Amortisation ( ml.) % Q Q

43 TELECINCO Back up Slides 43

44 TELECINCO TV Revenues Breakdown ( ml.) ITALIAN GAAP 1Q Q 2003 Net TV Advertising Revenues Gross TV Advertising Revenues Agency Commissions Other Net Revenues Total Net Revenues (10.9) (11.4)

45 TELECINCO TV Operating Costs Breakdown ( ml.) ITALIAN GAAP 1Q Q 2003 Personnel Costs TV Operating Costs Commercial Costs In-house Production Transmission Costs Overheads Total Operating Costs (16.8) (58.1) (1.1) (42.5) (4.3) (10.2) (74.9) (16.1) (49.3) (1.5) (35.3) (4.5) (8.0) (65.4) 45

46 TELECINCO Amortisation & Depreciation ( ml.) ITALIAN GAAP % ,1 Other Depreciation & Amortisation ( ml.) 3,7-27.5% TV Rights Amortisation & Depreciation ( ml.) 37,8-13.9% 43,9 1Q Q

47 TELECINCO Non Operating Items ( ml.) ITALIAN GAAP 1Q Q 2003 Total Associates 0.1 (0.7) Net Financial Income/(Charges) Total Extraordinary Items (0.2) (0.4) 47

48 TELECINCO Investments 58.4 ml ml Q Q TV Rights Tangible & Intangible Fixed Assets ITALIAN GAAP 48

49 DISCLAIMER Statements contained in this document, particularly the ones regarding any Mediaset Group possible or assumed future performance, are or may be forward looking statements and in this respect they involve some risks and uncertainties. Mediaset Group actual results and developments may differ materially from the ones expressed or implied by the above statements depending on a variety of factors. Any reference to past performance of Mediaset Group shall not be taken as an indication of future performance. The content of this document is not, and shall not be considered as, an offer document or an offer or solicitation to buy or sell any stock. 49

1Q 2009 Results Presentation. 12 May 2009

1Q 2009 Results Presentation. 12 May 2009 1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average

More information

2010 First Quarter Results Presentation. 11 th May 2010

2010 First Quarter Results Presentation. 11 th May 2010 2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Welcome to LG Electronics

Welcome to LG Electronics Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.

More information

1Q2005. Hera Group presentation

1Q2005. Hera Group presentation 1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE

WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

Woongjin Coway. 1Q 12 IR Presentation

Woongjin Coway. 1Q 12 IR Presentation Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This

More information

THIRD QUARTER REPORT 2011 (UNAUDITED)

THIRD QUARTER REPORT 2011 (UNAUDITED) THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700

More information

Coloplast A/S. Investor Presentation 2005/06

Coloplast A/S. Investor Presentation 2005/06 Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1 Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

Presentation of. Burgdorf, 1 st November 2012

Presentation of. Burgdorf, 1 st November 2012 Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

Passion for progress, care for people

Passion for progress, care for people Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.

More information

Budimex Group Presentation for investors for 1Q 2008

Budimex Group Presentation for investors for 1Q 2008 Budimex Group Presentation for investors for 1Q 2008 Our strategy 40 years on the market Building long term value backlog value significant growth and structure change solid platform for future growth

More information

Total Face Group Limited

Total Face Group Limited Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position

More information

1Q2017 法人說明會 Jun. 9, 2017

1Q2017 法人說明會 Jun. 9, 2017 1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic

More information

WntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE

WntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in

More information

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 KEY MESSAGES AGENDA 1Q 2015 RESULTS 2015 OUTLOOK & TARGETS 1Q 2015 TYRE OVERVIEW APPENDIX 1Q 2015 RESULTS 1 KEY MESSAGES > A solid 1Q 2015 with Premium outperformance

More information

METVIX PDT ON THE MARKET IN GERMANY AND UK

METVIX PDT ON THE MARKET IN GERMANY AND UK METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Leading Intimate Healthcare

Leading Intimate Healthcare 21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

PVD (PVDrilling) Company Visit October 2011

PVD (PVDrilling) Company Visit October 2011 PVD (PVDrilling) Company Visit October 2011 2011 Preview: 3Q11 EBT margin is expected to be higher than 2Q11 largely due to no booking of provision for Science and Technology Development Fund According

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Financial Results of the Asseco Group for the 1 st quarter of Warsaw, 14 May 2009

Financial Results of the Asseco Group for the 1 st quarter of Warsaw, 14 May 2009 Financial Results of the Asseco Group for the 1 st quarter of 2009 Warsaw, 14 May 2009 Agenda Summary of the 1 st quarter of 2009 Nearest plans 2 Financial highlights Consolidated data Sales* Proprietary

More information

SPY Imaging for Surgeons

SPY Imaging for Surgeons SPY Imaging for Surgeons Forward-Looking Statements These slides accompany an oral presentation by Novadaq Technologies, Inc., which contains forwardlooking statements. Actual results may differ materially

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

APPLIANCE TELECOMMUNICATIONS

APPLIANCE TELECOMMUNICATIONS May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching

More information

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive

More information

Presentation First quarter 2006

Presentation First quarter 2006 Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial

More information

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007 Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor

More information

INVESTOR PRESENTATION SEPTEMBER 2017

INVESTOR PRESENTATION SEPTEMBER 2017 INVESTOR PRESENTATION SEPTEMBER 2017 DABUR OVERVIEW One of the oldest and largest FMCG Companies in the country World s largest in Ayurveda and natural healthcare Total reach of 6 mn outlets, one of the

More information

BancAnalysts Association of Boston Conference Presentation. November 3, 2017

BancAnalysts Association of Boston Conference Presentation. November 3, 2017 BancAnalysts Association of Boston Conference Presentation November 3, 2017 Disclaimer This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform

More information

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009 J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

Sirtex Medical Ltd Buy

Sirtex Medical Ltd Buy Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Results Briefing Junichi Yoshii President & Representative Director

Results Briefing Junichi Yoshii President & Representative Director Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

First Quarter Results to March 31, Shire plc April 25, 2008

First Quarter Results to March 31, Shire plc April 25, 2008 First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

Oncosil (OSL) 100% Disease Control Rate. Maintain Buy (Speculative) Rating SOURCE: BELL POTTER SECURITIES ESTIMATES

Oncosil (OSL) 100% Disease Control Rate. Maintain Buy (Speculative) Rating SOURCE: BELL POTTER SECURITIES ESTIMATES Analyst John Hester 612 8224 2871 Oncosil (OSL) 23 October 2017 Speculative See key risks on Page 3 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.

More information

ŚCIŚLE POUFNE. The Company's presentation

ŚCIŚLE POUFNE. The Company's presentation The Company's presentation Warsaw, May 2017 Key figures #1 Leader of the market of reinforced concrete prefabricated elements in Poland 4 plants manufacturing reinforced concrete prefabricated elements

More information

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

Small-Cap Research. Celator Pharma (CPXX-NASDAQ) Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for

More information

Group financial results for the first quarter 2008

Group financial results for the first quarter 2008 Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

NASDAQ: FHCO 2016 Annual Meeting

NASDAQ: FHCO 2016 Annual Meeting NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting

More information

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology

More information

Nobel Biocare Group Full Year Report 2005

Nobel Biocare Group Full Year Report 2005 Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full

More information

Slide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes

Slide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

MICROCAP LEADERSHIP SUMMIT

MICROCAP LEADERSHIP SUMMIT MICROCAP LEADERSHIP SUMMIT WESTIN CHICAGO NORTHWEST HOTEL ITASCA, IL SEPTEMBER 23, 2016 SAFE HARBOR STATEMENT This presentation may be deemed to contain certain forward-looking statements with respect

More information

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007 Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010 QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

Hemispherx Biopharma AMEX: HEB

Hemispherx Biopharma AMEX: HEB Hemispherx Biopharma AMEX: HEB Re-commercialization Proceeds with some delay Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

TELECONFERENCE Q August 2015

TELECONFERENCE Q August 2015 TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Interim report Second quarter 2017 and subsequent events (Unaudited)

Interim report Second quarter 2017 and subsequent events (Unaudited) SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities

More information

Medivir Q Conference call 18 February, 2016

Medivir Q Conference call 18 February, 2016 Medivir Q4-2015 Conference call 18 February, 2016 Niklas Prager CEO Ola Burmark CFO Richard Bethell EVP R&D A research-based pharmaceutical company with focus on infectious diseases and oncology Q4 Highlights

More information